Bezlotoxumab

Bezlotoxumab Abstract The purpose was to review the pharmacology, safety, and efficacy of bezlotoxumab (Zinplava; Merck Sharp & Dohme Corp, Whitehouse Station, NJ) as a novel therapy for prevention of recurrent Clostridium difficile infection (CDI). MEDLINE was searched (1946 to February 2017) using the terms bezlotoxumab, MK6072, MBL-CDB1, and MDX-1388. Additional studies were identified through searching FDA.gov, clinicaltrials.gov, and review of reference lists. Studies included were randomized control trials in English language on bezlotoxumab for recurrent CDI. Animal studies were excluded. Three randomized control trials were identified evaluating bezlotoxumab in adults receiving standard of care therapy for CDI. The primary outcome evaluated in all trials was CDI recurrence. A phase II trial found the combination of bezlotoxumab-actoxumab compared with placebo decreased CDI recurrence at 84 days (7% vs 25%, P < 0.001). Two similar, yet independent phase III trials evaluated recurrent CDI at 12 weeks. Results were consistent between the 2 trials and pooled analysis displayed a reduction in CDI recurrence in the bezlotoxumab group (absolute difference, −10.1%; 95% confidence interval, −14 to −6; P < 0.001) and the bezlotoxumab-actoxumab group (absolute difference, −11.5%; 95% confidence interval, −15.2 to −7.2; P < 0.001) compared with placebo. Initial and sustained clinical cure rates were similar between bezlotoxumab, bezlotoxumab-actoxumab, and placebo. Overall, the adverse effects associated with bezlotoxumab were similar to placebo, with diarrhea, nausea, pyrexia, and headache having a higher occurrence than placebo. In conclusion, bezlotoxumab is safe and effective at reducing CDI recurrence and the use of bezlotoxumab should be considered in patients who are at highest risk for CDI. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Infectious Diseases in Clinical Practice Wolters Kluwer Health

Loading next page...
 
/lp/wolters_kluwer/bezlotoxumab-tDPsnKK1xI
Publisher
Lippincott Williams & Wilkins
Copyright
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1056-9103
eISSN
1536-9943
D.O.I.
10.1097/IPC.0000000000000571
Publisher site
See Article on Publisher Site

Abstract

Abstract The purpose was to review the pharmacology, safety, and efficacy of bezlotoxumab (Zinplava; Merck Sharp & Dohme Corp, Whitehouse Station, NJ) as a novel therapy for prevention of recurrent Clostridium difficile infection (CDI). MEDLINE was searched (1946 to February 2017) using the terms bezlotoxumab, MK6072, MBL-CDB1, and MDX-1388. Additional studies were identified through searching FDA.gov, clinicaltrials.gov, and review of reference lists. Studies included were randomized control trials in English language on bezlotoxumab for recurrent CDI. Animal studies were excluded. Three randomized control trials were identified evaluating bezlotoxumab in adults receiving standard of care therapy for CDI. The primary outcome evaluated in all trials was CDI recurrence. A phase II trial found the combination of bezlotoxumab-actoxumab compared with placebo decreased CDI recurrence at 84 days (7% vs 25%, P < 0.001). Two similar, yet independent phase III trials evaluated recurrent CDI at 12 weeks. Results were consistent between the 2 trials and pooled analysis displayed a reduction in CDI recurrence in the bezlotoxumab group (absolute difference, −10.1%; 95% confidence interval, −14 to −6; P < 0.001) and the bezlotoxumab-actoxumab group (absolute difference, −11.5%; 95% confidence interval, −15.2 to −7.2; P < 0.001) compared with placebo. Initial and sustained clinical cure rates were similar between bezlotoxumab, bezlotoxumab-actoxumab, and placebo. Overall, the adverse effects associated with bezlotoxumab were similar to placebo, with diarrhea, nausea, pyrexia, and headache having a higher occurrence than placebo. In conclusion, bezlotoxumab is safe and effective at reducing CDI recurrence and the use of bezlotoxumab should be considered in patients who are at highest risk for CDI.

Journal

Infectious Diseases in Clinical PracticeWolters Kluwer Health

Published: Apr 1, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off